- $16.19m
- -$40.86m
- $0.19m
aTyr Pharma Inc reports results for the quarter ended in March - Earnings Summary
aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: aTyr Pharma Q1 Net Income USD -15.487 Million
aTyr Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: aTyr Pharma Q4 Net Income USD -14.761 Million
aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Atyr Pharma Announces Expanded Access Program (Eap) For Efzo-Fit™ Clinical Trial Participants
Brief: Atyr Pharma Announces Howard University President Emeritus Dr. Wayne Frederick As Advisor
Brief: Logos Global Management Lp Reports 9.9% Passive Stake In Atyr Pharma
Brief: Atyr Pharma Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: aTyr Pharma Q3 Net Income USD -11.342 Million
Brief: aTyr Pharma Announces Dosing Of First Patient In Phase 2 Efzo-Connect Study Of Efzofitimod In Patients With Ssc-Ild
aTyr Pharma Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP-Activision Blizzard, Forward Air, Netflix
Brief: European Commission Grants Orphan Drug Designation For aTyr Pharma’s Efzofitimod For Treatment Of Systemic Sclerosis
Brief: Atyr Pharma Announces First Quarter 2023 Results And Provides Corporate Update
aTyr Pharma Inc reports results for the quarter ended in March - Earnings Summary
aTyr Pharma Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Atyr Pharma -As Of March 10, 2023, Co Holds Less Than 2% Of Its Current Cash, Cash Equivalents, Restricted Cash & Available For Sale Investments With Svb